Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Heart Outcomes Prevention Evaluation-3 (HOPE-3)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Salim Yusuf's office, Population Health Research Institute
ClinicalTrials.gov Identifier:
NCT00468923
First received: May 2, 2007
Last updated: February 13, 2014
Last verified: February 2014

May 2, 2007
February 13, 2014
May 2007
October 2015   (final data collection date for primary outcome measure)
  • To evaluate the effects of lipid modification (LDL cholesterol lowering and HDL cholesterol raising) with rosuvastatin 10 mg daily on major CV events. [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • To evaluate the effects of blood pressure lowering with combined candesartan 16 mg/HCT 12.5 mg daily on major CV events. [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • To evaluate the impact of combined lipid modification with rosuvastatin 10 mg/day and blood pressure lowering with candesartan 16 mg/HCT 12.5 mg daily on major CV events. [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • To evaluate the effects of lipid modification (LDL cholesterol lowering and HDL cholesterol raising) with rosuvastatin 10 mg daily on major CV events.
  • To evaluate the effects of blood pressure lowering with combined candesartan 16 mg/HCT 12.5 mg daily on major CV events.
  • To evaluate the impact of combined lipid modification with rosuvastatin 10 mg/day and blood pressure lowering with candesartan 16 mg/HCT 12.5 mg daily on major CV events.
Complete list of historical versions of study NCT00468923 on ClinicalTrials.gov Archive Site
  • Total mortality [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • CV mortality [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Coronary heart disease events [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Cerebrovascular disease events [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Heart failure [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Revascularization procedures [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Angina pectoris [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Progression of renal disease [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • New diagnosis of diabetes [ Time Frame: Biannually ] [ Designated as safety issue: No ]
  • Total mortality
  • CV mortality
  • Coronary heart disease events
  • Cerebrovascular disease events
  • Heart failure
  • Revascularization procedures
  • Angina pectoris
  • Progression of renal disease
  • New diagnosis of diabetes
Not Provided
Not Provided
 
Heart Outcomes Prevention Evaluation-3
Heart Outcomes Prevention Evaluation-3

Heart disease and stroke are major causes of death and disability worldwide and are largely preventable. Cholesterol and blood pressure are major cardiovascular risk factors. Previous studies have shown that certain drugs can effectively and safely lower cholesterol and blood pressure and prevent heart attacks and strokes. Such studies have been conducted primarily in people who had already sustained a heart attack or a stroke, or in people with high cholesterol and blood pressure levels. However, most heart attacks and strokes occur in people with average ("normal") cholesterol and blood pressure. Therefore, in the HOPE-3 trial the investigators will evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/hydrochlorothiazide, used alone or together can reduce the risk of heart attacks, stroke and their sequelae in people without known heart disease and at average risk.

The trial has randomized 12,705 women 60 years or older and men 55 years or older without known heart disease or prior stroke and without a clear indication or contraindication to any of the study medications. Eligible and consenting individuals were randomized to receive either active study medications or placebo (dummy pills) and will be monitored for an average of 5.7 years. The rates of heart attacks, strokes, deaths and other cardiovascular events will be compared between subjects receiving the active drugs and those on placebo. The study included people from 21 countries, which were monitored by an international group of scientists and physicians. The study was coordinated by the Population Health Research Institute at McMaster University. The study is expected to demonstrate that combined lipid lowering and blood pressure lowering will substantially lower the risk for cardiovascular diseases and may substantially change our approach to cardiovascular prevention.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Cardiovascular Disease
  • Stroke
  • Drug: Candesartan/HCT
    Candesartan 16 mg/HCT 12.5 once daily
  • Drug: Rosuvastatin
    Rosuvastatin 10 mg once daily
  • Placebo Comparator: Rosuvastatin
    Rosuvastatin 10 mg vs placebo
    Intervention: Drug: Rosuvastatin
  • Placebo Comparator: Candesartan/HCT
    Candesartan 16 mg/HCT 12.5 mg vs placebo
    Intervention: Drug: Candesartan/HCT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
12705
March 2016
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women aged > 60 years and men > 55 years
  • At least one additional CV risk factor including:
  • Waist/hip ratio ≥ 0.90 in men and ≥ 0.85 in women;
  • History of current or recent smoking (regular tobacco use within 5 years)
  • Low HDL cholesterol
  • Dysglycemia
  • Renal dysfunction
  • Family history of premature CHD in first degree relatives

Exclusion Criteria:

  • Documented clinically manifest atherothrombotic CVD
  • Clear indication or contraindication for statin and/or ARB or ACE inhibitor and/or thiazide diuretic therapy
  • Symptomatic hypotension
  • Chronic liver disease
  • Inflammatory muscle disease
  • Renal impairment
  • Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine
  • Concurrent treatment with a statin, fibrate, angiotensin receptor blocker, ACE inhibitor, or a thiazide diuretic
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the trial
  • Significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the trial procedures
  • Concurrent use of an experimental pharmacological agent
Both
55 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00468923
PHRI
Yes
Salim Yusuf's office, Population Health Research Institute
Population Health Research Institute
Not Provided
Principal Investigator: Salim Yusuf, DPhil FRCPC McMaster University
Principal Investigator: Eva Lonn, MD MSc FRCPC McMaster University
Population Health Research Institute
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP